Focus Area 14 Title Immunization and Infectious Diseases Goal Prevent disease, disability, and death from infectious diseases, including vaccine-preventable diseases.

Obj Num	Category	Objective	2010 US Target		Population Description	Lead Agency		Type of Interest		Data Source	UT Baseline	UT Target	UT Target Selection
14.01a	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Congenital rubella syndrome (number of cases, children under 1 year)	0	main		ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010
14.01b	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Diphtheria (number of cases, ages under 35 years)	0	main		ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010
14.01c	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Haemophilus influenzae type b and unknown serotype - Children - (number of cases, children aged under 5 years)	0	main		ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010
14.01d	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Hepatitis B (number of cases, ages 2 to 18 years)	9	main		ELS(Epi) CFHS (im)		S&I	NO	NETSS	4	0	HP2010
14.01e	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Measles (number of cases)	0	main		ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	3	0	HP2010
14.01f	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Mumps (number of cases)	0	main		ELS(Epi) CFHS (im)		S&I	NO	NETSS	7	0	HP2010
14.01g	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Pertussis Children (number of cases, children aged under 7 years)	2000	main		ELS(Epi) CFHS (im)		S&I	NO	NETSS	29	20	HP2010
14.01h	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Polio (wild-type virus) (number of cases)	0	main		ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010

14.01i	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Rubella (number of cases)	0	main	ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010
14.01j	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Tetanus (number of cases, ages under 35 years)	0	main	ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	0	0	HP2010
14.01k	Diseases Preventable Through Universal Vaccination	Vaccine-preventable diseases - Varicella (chicken pox) (number of cases (thousands), ages 18 years and under)	400	main	ELS(Epi) CFHS (im)	UDOH	S&I	NO	NETSS	74	50	HP2010
14.02	Diseases Preventable Through Universal Vaccination	Hepatitis B in infants and young children -Perinatal infections (number of cases, children aged under 2 years)	400	main	ELS(Epi) CFHS (im)	D/P	S&I	NO	NETSS	4 cs<2 yrs	0 cs<2 yrs	HP2010
14.03a	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 19 to 24 years	2.4	main	ELS (Epi)	D/P	S&I	NO	NETSS	2.04	0.02	HP2010
14.03b	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 25 to 39 years)	5.1	main	ELS (Epi)	D/P	S&I	NO	NETSS	2.6	0.65	HP2010
14.03c	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 40 years and older)	3.8	main	ELS (Epi)	D/P	S&I	NO	NETSS	2	0.5	HP2010
14.03d	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups - High risk groups - Injection drug users (number of cases)	1808	main	ELS (Epi)	D/P	S&I	NO	NETSS	7	2	HP2010
14.03e	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups - High risk groups - Heterosexually active persons (number of cases)	1240	main	ELS (Epi)	D/P	S&I	NO	NETSS	19	2	HP2010

14.03f	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups - High risk groups - Men who have sex with men (number of cases)	1808	main	ELS (Epi)	D/P	S&I	NO	NETSS	0	0	HP2010
14.03g	Diseases Preventable Through Universal Vaccination	Hepatitis B in adults and high-risk groups - High risk groups - Occupationally exposed workers (number of cases)	62	main	ELS (Epi)	-	NS	-	-	NA	NA	HP2010
14.04	Diseases Preventable Through Universal Vaccination	Bacterial meningitis in young children (new cases per 100,000 population, children 1 to 23 months)	8.6	main	ELS (Epi)	D/P	S&I	NO	NETSS	12/100K	7.9/100K	HP2010
14.05a	Diseases Preventable Through Universal Vaccination	Invasive pneumoccoccal infections - Children (new cases per 100,000 population, children aged under 5 years)	46	main	ELS (Epi)	D/P	S&I	NO	NETSS	2.74	1.6	HP2010
14.05b	Diseases Preventable Through Universal Vaccination	Invasive pneumoccoccal infections - Adults (new cases per 100,000 population, ages 65 years and older)	42	main	ELS (Epi)	D/P	S&I	NO	NETSS	2.75	1.8	HP2010
14.05c	Diseases Preventable Through Universal Vaccination	Invasive pneumoccoccal infections - Penicillin-resistant - Children (new cases per 100,000 population, children aged under 5	6	main	ELS (Epi)	D/P	S&I	NO	NETSS	NA	NA	HP2010
14.05d	Diseases Preventable Through Universal Vaccination	Invasive pneumoccoccal infections - Penicillin-resistant - Adults (new cases per 100,000 population, ages 65 years and older)	7	main	ELS (Epi)	D/P	S&I	NO	NETSS	NA	NA	HP2010
14.06	Diseases Preventable Through Targeted Vaccination	Hepatitis A - (new cases per 100,000 population)	4.5	main	ELS(Epi) CFHS (im)	D/P	S&I	NO	NETSS	3.3/100K	1.3/100K	HP2010
14.07	Diseases Preventable Through Targeted Vaccination	Meningococcal disease - (new cases per 100,000 population)	1	main	ELS (Epi)	D/P	S&I	NO	NETSS	0.3/100K	0.25/100K	HP2010

14.08	Diseases Preventable Through Targeted Vaccination	Lyme disease - In endemic States (new cases per 100,000 population)	9.7	main	ELS (Epi)		NS					
14.09	Infectious Diseases and Emerging Antimicrobial Resistance	Hepatitis C - (new cases per 100,000 population)	1	main	ELS (Epi)	D/P	S&I	NO	NETSS	0.6/100K	0.25/100K	HP2010
14.10	Infectious Diseases and Emerging Antimicrobial Resistance	Identification of persons with chronic hepatitis	DNC	main	ELS (Epi)		NS					
14.11	Infectious Diseases and Emerging Antimicrobial Resistance	Tuberculosis - (new cases per 100,000 population)	1	main	ELS (HIV)	D/P	S&I	NO	TIMS	2.3/100K	0.8/100K	75% REDUCTION
14.12	Infectious Diseases and Emerging Antimicrobial Resistance	Curative therapy for tuberculosis	0.9	main	ELS (HIV)	D/P	S&I	NO	TIMS	0.74	0.9	HP2010
14.13	Infectious Diseases and Emerging Antimicrobial Resistance	Treatment for high-risk persons with latent tuberculosis infection	0.85	main	ELS (HIV)	D/P	S&I	NO	UNDER DEVELOPM NT	E	0.85	HP2010
14.14	Infectious Diseases and Emerging Antimicrobial Resistance	Timely laboratory confirmation of tuberculosis cases - Average number of days to report 75% of cases	2	main	ELS (HIV/LAB)	D/P	S&I	NO	TIMS	17 DAYS	12 DAYS	LAB STAFF
14.15	Infectious Diseases and Emerging Antimicrobial Resistance	Prevention services for international travelers	DNC	main	ELS (Epi)		NS					
14.16	Infectious Diseases and Emerging Antimicrobial Resistance	Invasive early onset group B streptococcal disease (per 1,000 live births)	0.5	main	ELS (Epi)		NS					

14.17	Infectious Diseases and Emerging Antimicrobial Resistance	Peptic ulcer hospitalizations (age adjusted per 100,000 standard population)	46	main	ELS (Epi)	NS					
14.18	Infectious Diseases and Emerging Antimicrobial Resistance	Antibiotics prescribed for ear infections -Children (courses prescribed per 100 population, children aged under 5 years)	88	main	ELS (Epi) NI	NS			NOT RPRTEI TO UDOH	D	
14.19	Infectious Diseases and Emerging Antimicrobial Resistance	Antibiotics prescribed for common cold (courses prescribed per 100,00 population)	1268	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.20a	Infectious Diseases and Emerging Antimicrobial Resistance	Hospital-acquired infections - Adult intensive care patients - Catheter-associated urinary tract infection (per 1,000 days use)	5.3	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.20b	Infectious Diseases and Emerging Antimicrobial Resistance	Hospital-acquired infections - Adult intensive care patients - Central line-associated bloodstream infection (per 1,000 days use)	4.8	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.20c	Infectious Diseases and Emerging Antimicrobial Resistance	Hospital-acquired infections - Adult intensive care patients - Ventilator-associated pneumonia (per 1,000 days use)	10	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.20d	Infectious Diseases and Emerging Antimicrobial Resistance	Hospital-acquired infections - Infant intensive care patients - Central line-associated bloodstream infection (weighing 1,000 grams or less) (per 1,000 days use)	11	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.20e	Infectious Diseases and Emerging Antimicrobial Resistance	Hospital-acquired infections - Infant intensive care patients - Ventilator-associated pneumonia (for infants weighing 1,000 grams or less) (per 1,000 days use)	4.4	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.21	Infectious Diseases and Emerging Antimicrobial Resistance	Antimicrobial use in intensive care units (daily doses per 1,000 patient days)	120	main	ELS (Epi)	NS			NOT RPRTEI TO UDOH	D	
14.22a	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 4 doses diphtheria-tetanus-acellular pertussis (DtaP)	0.9	main	ELS(Epi) UDOH CFHS (im)	S&I	N	State CASA, CDC-NIS	, 0.823	0.9	HP 2010

14.22b	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 3 doses Haemophilus influenzae type b (Hib) vaccine	0.9	main	CFHS (im)	NS				
14.22c	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 3 doses hepatis B (hep B) vaccine	0.9	main	CFHS (im)	NS				
14.22d	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 1 dose measles-mumps-rubella (MMR) vaccine	0.9	main	CFHS (im)	NS				
14.22e	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 3 doses polio vaccine	0.9	main	CFHS (im)	NS				
14.22f	Vaccination Coverage and Strategies	Universally recommended vaccination of children 19 to 35 months - 1 dose varicella vaccine	0.9	main	CFHS (im)	NS				
14.23a	Vaccination Coverage and Strategies	Diphtheria-tetanus-acellular pertussis (DtaP) vaccine coverage, children in day care	0.95	main	CFHS (im) UDOH	S&I	N	Utah Annual 0.937 School Report, CDC	0.95	HP 2010
14.23b	Vaccination Coverage and Strategies	Measles-mumps-rubella (MMR) vaccine coverage, children in day care	0.95	main	CFHS (im)	NS				
14.23c	Vaccination Coverage and Strategies	Polio vaccine coverage, children in day care	0.95	main	CFHS (im)	NS				
14.23d	Vaccination Coverage and Strategies	Hepatitis B vaccine coverage, children in day car	DNC	main	CFHS (im)	NS				
14.23e	Vaccination Coverage and Strategies	Varicella vaccine coverage, children in day	DNC	main	CFHS (im)	NS				
14.23f	Vaccination Coverage and Strategies	Diphtheria-tetanus-acellular pertussis (DtaP) vaccine coverage, children in kindergarten and first grade	0.95	main	CFHS (im)	NS				
14.23g	Vaccination Coverage and Strategies	Measles-mumps-rubella (MMR) vaccine coverage, children in kindergarten and first grade	0.95	main	CFHS (im)	NS				
14.23h	Vaccination Coverage and Strategies	Polio vaccine coverage, children in kindergarten and first grade	0.95	main	CFHS (im)	NS				
14.23i	Vaccination Coverage and Strategies	Hepatitis B vaccine coverage, children in kindergarten and first grade	DNC	main	CFHS (im)	NS				
14.23j	Vaccination Coverage and Strategies	Varicella vaccine coverage, children in kindergarten and first grade	DNC	main	CFHS (im)	NS				

(Vaccination Coverage and Strategies	Fully immunized young children and adolescents -Children 19 to 35 months	0.8	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Fully immunized young children and adolescents -Adolescents aged 13 to 15 years	DNC	main	ELS(Epi) CFHS (im)	NS					
(Vaccination Coverage and Strategies	Providers who measure childhood vaccination coverage levels - Public health providers	0.9	main	CFHS (im) D/P	S&I	N	CDC	6 (national baseline)	0.9	HP 2010
(Vaccination Coverage and Strategies	Providers who measure childhood vaccination coverage levels - Private providers	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Children participating in population-based immunization registries (children aged under 6 years)	0.95	main	CFHS (im) D/P	S	N	USIIS, CDC NIP	, 0.399	0.95	HP 2010
(Vaccination Coverage and Strategies	Vaccination coverage among adolescents - 3 or more doses of hepatitis B (adolescents aged 13 to 15 years)	0.9	main	CFHS (im) D/P	S&I	N	Utah Annua School Report, CD0		0.95	HP 2010
(Vaccination Coverage and Strategies	Vaccination coverage among adolescents - 2 or more doses of measles, mumps, rubella (adolescents aged 13 to 15 years)	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Vaccination coverage among adolescents - 1 or more doses of tetanus-diptheria booster (adolescents aged 13 to 15 years)	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Vaccination coverage among adolescents - 1 or more doses of varicella (excluding adolescents who have varicella) (adolescents aged 13 to 15 years)	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Hepatitis B vaccination among high-risk groups -Long-term hemodialysis patients	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Hepatitis B vaccination among high-risk groups -Men who have sex with men	0.6	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Hepatitis B vaccination among high-risk groups -Occupationally exposed workers	0.98	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Influenza vaccine (age adjusted, ages 65 years and older)	0.9	main	CFHS (im)	NS					
(Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Influenza vaccine (age adjusted, ages 65 years and older)	0.9	sub1 Adults Age 65+ with Diabetes Mellitus	CFHS D/P (diabetes)	S&I	N	Medicare/BF FSS	R 0.465	0.9	US Target

14.29b Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Pneumococcal vaccine (age adjusted, ages 65 years and older)	0.9	main	CFHS (im)	NS				
14.29b Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Pneumococcal vaccine (age adjusted, ages 65 years and older)	0.9	sub1 Adults Age 65+ with Diabetes Mellitus	CFHS D/P (diabetes)	S&I N	Medi FSS	care/BR 0.241	0.9	US Target
14.29c Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Influenza vaccine (age adjusted, ages 18 to 64 years)	0.6	main	CFHS (im)	NS				
14.29c Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Influenza vaccine (age adjusted, ages 18 to 64 years)	0.6	sub1 Adults Age 18-64 with Diabetes Mellitus	CFHS D/P (diabetes)	S&I N	BRFS	SS 0.445	0.6	US Target
14.29d Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Pneumococcal vaccine (age adjusted, ages 18 to 64 years)	0.6	main	CFHS (im)	NS				
14.29d Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Pneumococcal vaccine (age adjusted, ages 18 to 64 years)	0.6	sub1 Adults Age 18-64 with Diabetes Mellitus	CFHS D/P (diabetes)	S&I N	BRFS	SS 0.23	0.6	US Target
14.29e Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Institutionalized - Influenza vaccine (ages 18 years and older)	0.9	main	CFHS (im)	NS				
14.29f Vaccination Coverage and Strategies	Influenza and pneumococcal vaccination of high-risk adults - Institutionalized - Pneumococcal vaccine (ages 18 years and older)	0.9	main	CFHS (im)	NS				
14.30a Vaccine Safety	Adverse events from vaccinations - Associated paralytic polio (number of VAPP	0	main	CFHS (im)	NS				
14.30b Vaccine Safety	Adverse events from vaccinations - Febrile seizures caused by pertussis vaccines	75	main	CFHS (im)	NS				
14.31 Vaccine Safety	Active surveillance for vaccine safety via large linked databases (number (millions))	13	main	CFHS (im)	NS				